ACRS

Aclaris Therapeutics Inc

Apr 09 • 04:00PM ET

4.08

+0.13 3.29 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX PCRX AGIO SRPT BMRN ALKS ENTA KYNB VKTX XERS

| Held by: VTI IWM IWN VXF IBB VTWO ITOT VFMO IWC PRFZ

Index	RUT	P/E	-	EPS (ttm)	-0.53	Insider Own	14.83%	Shs Outstand	120.50M	Perf Week	-1.45%
Market Cap	492.03M	Forward P/E	-	EPS next Y	-0.66	Insider Trans	0.00%	Shs Float	102.71M	Perf Month	11.17%
Enterprise Value	403.40M	PEG	-	EPS next Q	-0.16	Inst Own	72.97%	Short Float	4.57%	Perf Quarter	52.24%
Income	-64.92M	P/S	62.84	EPS this Y	-20.26%	Inst Trans	-3.24%	Short Ratio	1.97	Perf Half Y	121.74%
Sales	7.83M	P/B	4.77	EPS next Y	-3.93%	ROA	-34.10%	Short Interest	4.70M	Perf YTD	35.55%
Book/sh	0.86	P/C	5.42	EPS next 5Y	-13.36%	ROE	-50.20%	52W High	4.89 -16.56%	Perf Year	237.19%
Cash/sh	0.75	P/FCF	-	EPS past 3/5Y	26.48% 15.08%	ROIC	-62.04%	52W Low	1.05 288.57%	Perf 3Y	-55.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-35.93% 3.84%	Gross Margin	6.93%	Volatility	7.09% 7.43%	Perf 5Y	-85.91%
Dividend TTM	-	EV/Sales	51.52	EPS Y/Y TTM	64.96%	Oper. Margin	-943.97%	ATR (14)	0.27	Perf 10Y	-79.76%
Dividend Ex-Date	-	Quick Ratio	3.36	Sales Y/Y TTM	-58.20%	Profit Margin	-829.58%	RSI (14)	60.16	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	3.36	EPS Q/Q	84.07%	SMA20	9.63%	Beta	0.72	Target Price	8.94
Payout	-	Debt/Eq	0.02	Sales Q/Q	-85.94%	SMA50	16.85%	Rel Volume	0.45	Prev Close	3.95
Employees	73	LT Debt/Eq	0.02	Earnings	Feb 26 BMO	SMA200	59.80%	Avg Volume	2.39M	Price	4.08
IPO	Oct 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.57% -37.47%	Trades		Volume	1,064,157	Change	3.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Piper Sandler	Overweight	$6
May-28-25	Initiated	Wedbush	Outperform	$8
Mar-18-25	Resumed	Cantor Fitzgerald	Overweight
Dec-23-24	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform	$2 → $7
Nov-19-24	Upgrade	Jefferies	Hold → Buy	$2 → $7
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy	$8
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight	$3 → $13
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform	$22
Dec-14-22	Initiated	Stifel	Buy	$29
Dec-01-22	Initiated	Goldman	Buy	$25
Oct-06-22	Initiated	BTIG Research	Buy	$32
Jul-23-21	Resumed	Jefferies	Buy	$27 → $32
Jun-15-21	Initiated	Piper Sandler	Overweight	$30
Apr-21-21	Initiated	H.C. Wainwright	Buy	$40
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Show Previous Ratings

Apr-08-26 08:30AM	Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference (GlobeNewswire) +5.33%
Mar-27-26 10:10AM	Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 (GlobeNewswire)
Mar-20-26 11:00AM	Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-18-26 06:55AM	Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis (GlobeNewswire) -5.67%
Mar-03-26 07:00AM	Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
10:59AM	Loading…
Feb-26-26 10:59AM	Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference (MarketBeat) -5.44%
09:45AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Aclaris: Q4 Earnings Snapshot (Associated Press Finance)
06:58AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-26 12:15PM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-26 09:55PM	Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:00AM	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052 (GlobeNewswire)
Feb-12-26 07:27PM	Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 (MarketBeat) -5.06%
Feb-04-26 07:00AM	Aclaris Therapeutics to Participate in Two February Healthcare Conferences (GlobeNewswire)
Jan-27-26 01:12PM	Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug (Benzinga)
06:55AM	Loading…
06:55AM	Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) (GlobeNewswire)
Jan-13-26 07:44AM	Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 (TipRanks)
Jan-12-26 06:55AM	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 (GlobeNewswire)
Jan-06-26 06:59AM	Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development (GlobeNewswire)
Dec-19-25 04:01PM	Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) (GlobeNewswire)
Nov-25-25 08:00AM	Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 08:05AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:08AM	Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
06:59AM	Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 06:25PM	Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates (Zacks) -7.81%
Oct-29-25 07:30AM	Aclaris Therapeutics to Participate in Three November Healthcare Conferences (GlobeNewswire)
Oct-21-25 12:00PM	What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now? (Zacks) +18.41%
Sep-30-25 07:00AM	Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 (GlobeNewswire)
Sep-21-25 09:13AM	Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight (Insider Monkey)
Sep-18-25 10:05AM	Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? (Zacks) +7.73%
07:00AM	Loading…
Sep-09-25 07:00AM	Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Aug-27-25 08:00AM	Aclaris Therapeutics to Participate in Two September Healthcare Conferences (GlobeNewswire)
Aug-17-25 11:41PM	Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138 (Insider Monkey)
Aug-07-25 08:05AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:07AM	Aclaris: Q2 Earnings Snapshot (Associated Press Finance)
06:59AM	Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-25 10:00AM	Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-30-25 10:00AM	Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-29-25 04:01PM	Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints (GlobeNewswire) -7.74%
Jul-28-25 08:45AM	Aclaris Therapeutics Announces Leadership Transition (GlobeNewswire)
Jul-15-25 08:59AM	Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases (Insider Monkey)
Jun-30-25 09:31AM	Aclaris Therapeutics Added to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-26-25 04:01PM	Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference (GlobeNewswire) -5.77%
Jun-23-25 06:59AM	Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 (GlobeNewswire)
Jun-02-25 06:59AM	Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis (GlobeNewswire)
May-28-25 09:20AM	Aclaris Therapeutics to Participate in Two June Healthcare Conferences (GlobeNewswire) +11.02%
May-09-25 07:00AM	Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series (GlobeNewswire)
May-08-25 08:00AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:57AM	Aclaris: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-23-25 06:44AM	Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052 (Clinical Trials Arena) +8.18%
Apr-22-25 06:59AM	Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody (GlobeNewswire)
Mar-19-25 08:21AM	Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald (TipRanks)
Mar-04-25 07:00AM	Aclaris Therapeutics to Participate in Two March Healthcare Conferences (GlobeNewswire)
Feb-27-25 08:20AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -7.14%
07:21AM	Aclaris: Q4 Earnings Snapshot (Associated Press Finance)
06:59AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-12-25 06:50AM	New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 (GlobeNewswire)
Jan-30-25 04:01PM	Aclaris Therapeutics Announces Formation of New Scientific Advisory Board (GlobeNewswire)
Jan-06-25 04:30PM	Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 04:30PM	Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 04:30PM	Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) -9.02% +5.23%
Nov-20-24 05:11AM	Aclaris Therapeutics upgraded to Buy from Hold at Jefferies (TipRanks) -13.73%
Nov-19-24 09:30PM	Aclaris Therapeutics upgraded to Buy from Neutral at BTIG (TipRanks) +46.18%
03:27PM	Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments (Benzinga)
11:00AM	Aclaris Therapeutics secures global rights to Biosions antibodies (Pharmaceutical Technology)
Nov-18-24 08:50AM	Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets (PR Newswire) +53.17%
08:10AM	Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline (GlobeNewswire)
08:10AM	Aclaris Therapeutics Announces $80 Million Private Placement (GlobeNewswire)
Nov-06-24 08:05AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-09-24 07:02PM	Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc (GuruFocus.com)
Sep-18-24 06:52AM	Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial (Clinical Trials Arena)
Sep-17-24 07:00AM	Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis (GlobeNewswire)
Sep-10-24 07:00AM	Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-07-24 08:15AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:20AM	Aclaris: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-25-24 09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-16-24 04:01PM	Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million (GlobeNewswire)
Jul-02-24 01:27PM	Hedge Fund and Insider Trading News: Bill Ackman, David Einhorn, Saba Capital Management, Segantii Capital Management, Two Sigma Advisors, Falcon Investment Management, Aclaris Therapeutics Inc (ACRS), GigaCloud Technology Inc (GCT), and More (Insider Monkey)
Jun-06-24 07:00AM	Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-08-24 12:06PM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -8.96%
07:43AM	Q1 2024 Aclaris Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
May-07-24 10:56PM	ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:15PM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Aclaris: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-30-24 07:00AM	Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update (GlobeNewswire)
Apr-23-24 08:00AM	Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer (PR Newswire)
Apr-05-24 09:40AM	Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year? (Zacks)
Mar-20-24 09:40AM	Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire) -8.00%
Mar-04-24 12:00PM	Aclaris (ACRS) Upgraded to Buy: Here's Why (Zacks)
09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-27-24 09:35AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:38AM	Aclaris: Q4 Earnings Snapshot (Associated Press Finance)

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACRS

Aclaris Therapeutics Inc

Upgrade your Finviz experience